Gene · 8451
NIH grants1,323
NIH grants whose papers are about the gene, through NIH's grant-paper links.
41 to 60 of 1,323
Download this page as JSON| Grant | Title | CUL4A papers | Newest fiscal year |
|---|---|---|---|
| R01AI110762 | Molecular Mechanisms of HBV cccDNA Formation | 2 | 2025 |
| R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 2 | 2025 |
| R01CA140964 | Autophagy-mediated defense against inflammation and cancer | 2 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 2 | 2025 |
| R01CA240981 | Harnessing E3 Ligases for Cancer Therapy | 2 | 2025 |
| R01ES032786 | Integrative Modeling of Biomolecular Machinery in Nucleotide Excision Repair | 2 | 2025 |
| R01GM129325 | ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale Modeling | 2 | 2025 |
| R01HL098316 | Mechanism and regulation of DNA interstrand cross-link repair | 2 | 2025 |
| R01HL132182 | Novel Role of Bscl2 in Cardiac Substrate Metabolism and Function | 2 | 2025 |
| R35CA197569 | Mutations of Chromatin and its Modifying Machineries in Malignancies | 2 | 2025 |
| R35CA220430 | Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC) | 2 | 2025 |
| R35CA231997 | Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies | 2 | 2025 |
| R35CA263814 | Tackling Undruggable Cancer Targets using Chemoproteomic Platforms | 2 | 2025 |
| R35GM131780 | Protein-nucleic acid interactions in basic cellular processes | 2 | 2025 |
| T32AI007413 | Research Training in Experimental Immunology | 2 | 2025 |
| T32AI055434 | Training Program in Microbial Pathogenesis | 2 | 2025 |
| T32AI060537 | Integrative Microbiology Program | 2 | 2025 |
| T32CA009302 | Leveraging innovative technologies in basic and clinical cancer research | 2 | 2025 |
| ZIABC006150 | DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs | 2 | 2025 |
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8451/grants?page=3